Biopeople

Excellent histone researcher

Excellent histone researcher

19.03.2013 - Geneviève Almouzni will be handed over the prestigous FEBS | EMBO Women in Science Award in July.

The deputy director of the Institut Curie in Paris, France has been recognized with €10,000 for her outstanding research in the field  of epigenetics, especially the role histones and chromatin assembly in gene activity control. Almouzni started her professional career in the laboratory of Marcel Méchali, where she managed to identify critical molecular mechanisms regulating DNA replication and chromatin assembly. After completing a CNRS research assistant position in 1991, she moved to the lab of Alan Wolffe, a scientist who turned the chromatin field into a mainstream research subject. In 1994, Geneviève Almouzni was awarded a junior investigator grant of the CNRS and started as a junior group leader at the Institut Curie. Recently, she received an ERC Advanced Investigator grant and obtained a Laboratory of Excellence grant from the French Ministry of Research. 

16.01.2013 OBN, the trade association building the community for UK Bioscience companies, has named David Boal as Director of Business Development.

Boal joins OBN with an admirable sales record having worked with many of the major bioscience players and his own very successful consultancy. He graduated from the University of Ulster with a degree in Biomedical Sciences obtained whilst working at the MS research laboratories of Queens University in Belfast. Over the past 25 years David has achieved significant success in a number of sales, marketing and business development roles all within the Bio-pharmaceutical arena for companies such as, GD Searle (now Pfizer where he held a number of Sales & Marketing positions, Scotia, PolyMasc (Valentis), Laxdale and Amarin Neuroscience. Finally in the last 3 years, Boal has been running and managing his own business development consulting company (Diligent Consulting Ltd).

18.01.2013 Roche has appointed John Reed head of Roche Pharma Research and Early Development (pRED).

Reed succeeds Mike Burgess, who has led the Basel-headquartered research arm on an interim basis and will leave Roche. Reed previously was CEO at Sanford-Bunrham Medical research Institute in La Jolla..Reed is one of the world’s leading biomedical researchers with a focus on cancer, neuroprotection, autoimmunity, and other diseases and has authored several hundred medical research publications He is an inventor of more than one hundred patents and the founder or co-founder of a number of biotechnology companies.

22.01.2013 Swiss Siegfried Holding AG has hired former Evotec CFO Colin Bond to its Board.

In mid-April Siegfried’s shareholders will propose the appointment of the Swiss-British citizen. Before joining Evotec in 2010 Bond has been working as CFO with several international companies in various industries.

05.02.2013 Cancer expert Setareh van Driel Shamsili has taken up a new post as Chief Medical officer (CMO) at Dutch therapeutic antibody specialist Merus B.V.

 The neuro-oncologist comes in from Astellas Pharma Global Development, where she has been Medical Leader Oncology for the last eight years. She has been in translational and clinical cancer research for over a decade.

29.01.2013 Instead of renewing his contract, Bayer Healthcare AG Chairman Jörg Reinhardt (56) is seeking new opportunities.

The member of Bayer‘s Executive Council is standing for election as Director and non-executive Chairman at Novartis, and hopes to follow Daniel Vasella in the post. Board member Wolfgang Plischke will take over Reinhardt's role at Bayer. The pharma executive is returning to his roots. He began his career with Sandoz in 1981, which became part of Novartis 15 years later. In 2008, Reinhardt became COO of the Novartis Group, and in 2012 he was appointed to the Board of Lonza Group AG in Basel.

Photo: Bayer HealthCare

31.01.2013 Thomas Monath has been appointed as a consultant CMO at Austrian vaccine specialist Hookipa Biotech AG.

Monath, who will contribute input to the firm's R&D and development strategy, is a former partner in the Pandemic and Biodefense Fund (Kleiner Perkins Caufield & Byers), and an Adjunct Professor at the Harvard School of Public Health. Between 1992 and 2006, he was Chief Scientific Officer and Executive Director of British Acambis plc,  where he pioneered the development of numerous vaccines against various infectious diseases. Acambis was taken over by Sanofi in 2008 for £285m.

19.02.2013 Former Global Oncology Head from Sanofi-Aventis Alain Herrera joins the Nanobiotix team as a member of the Supervisory Board.

The Former Global Oncology Head at Sanofi brings in more than 25 years of experience in the pharmaceutical industry. Before setting up his own oncology consultancy – Alain Oncologie Consulting (AOC) -, he headed the Oncology business at Sanofi-Aventis for ten years.Previously, Herrera was Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc). In addition to these roles, since 1991, Dr. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital.

19.02.2013 Larry Bell has joined Leiden-based Prosensa Therapeutics as VP Global Regulatory Affairs.

He will be based in the US, said the Dutch specialist for RNA-modulating therapeutics. He brings in more than 18 years experience in running regulatory affairs and has worked with Merck, Bristol-Myers Squibb, Aventis and Amgen. Before setting up his own consultancy, in his most recent role he was Vice President and Global Head of Regulatory Affairs at GE Healthcare. He completed his MD at the University of Texas Medical Branch.

19.02.2013 Three researchers – one from the UK and two from Germany – have been awarded the Louis-Jeantet prize for Medicine.

Michael Stratton, Chief of the Wellcome Trust Sanger Institute in Hinxton, UK, and the two German biochemists Peter Hegemann, Berlin, and Georg Nagel, Würzburg (photo), will receive a prize money of CHF700,000. Stratton got the prize, of which CHF75,000 is for personal use, for his work aimed at understanding the genetic causes of human cancer. He discovered the roles of the BRCA2 and BRAF genes in breast and skin cancers. Hegemann and Nagel, who share the prize, pioneered the field of optogenetics, a technique to control gene expression by switching light on and off. Namely, they discovered ion channels that can be activated by light.

07.03.2013 German Alzheimer specialist Probiodrug AG has widened its management team by two new positions. Ronald Black will take over as Chief Medical Officer, while Inge Lues has been appointed Chief Development Officer.

Before joining Probiodrug, Black held various senior research roles at Pfizer and at Wyeth Pharmaceuticals prior to its acquisition by Pfizer. Most recently he was the assistant vice president of the firm's Alz-heimer immunotherapy programme. The native of the US has been involved with two New Drug Applications and eight Investigational New Drug filings, and has authored more than 40 publications. From 2008 until joining Probiodrug, Inge Lues acted as an R&D adviser to venture capital and biotechnology companies. During this period, she helped Probiodrug identify drug candidates and advance them into clinical studies. Previously the physiologist was the Executive Vice President Global Drug Discovery and Non-clinical Development at German Merck KGaA (Darmstadt).

Vorherige Seite1/8Nächste Seite

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • MORPHOSYS (D)72.25 EUR3.96%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • OREXO (S)137.00 SEK-5.35%

TOP

  • WILEX (D)3.10 EUR307.9%
  • SANTHERA (CH)67.95 CHF88.7%
  • ADDEX (CH)4.03 CHF79.9%

FLOP

  • MERCK KGAA (D)64.38 EUR-49.4%
  • HYBRIGENICS (F)1.77 EUR-27.5%
  • CHRONTECH PHARMA (S)0.07 SEK-22.2%

TOP

  • SANTHERA (CH)67.95 CHF3457.6%
  • GW PHARMACEUTICALS (UK)419.75 GBP715.0%
  • PAION (D)2.77 EUR313.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 27.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products